

Live-cell imaging RNAi screen identifies PP2A–B55 α and importin- β 1 as key mitotic exit regulators in human cells

Michael H. A. Schmitz^{1,2,3}, Michael Held^{1,2}, Veerle Janssens⁴, James R. A. Hutchins⁵, Otto Hudecz⁶, Elitsa Ivanova⁴, Jozef Goris⁴, Laura Trinkle-Mulcahy⁷, Angus I. Lamond⁸, Ina Poser⁹, Anthony A. Hyman⁹, Karl Mechtler^{5,6}, Jan-Michael Peters⁵ and Daniel W. Gerlich^{1,2,10}

When vertebrate cells exit mitosis various cellular structures are re-organized to build functional interphase cells¹. This depends on Cdk1 (cyclin dependent kinase 1) inactivation and subsequent dephosphorylation of its substrates^{2–4}. Members of the protein phosphatase 1 and 2A (PP1 and PP2A) families can dephosphorylate Cdk1 substrates in biochemical extracts during mitotic exit^{5,6}, but how this relates to postmitotic reassembly of interphase structures in intact cells is not known. Here, we use a live-cell imaging assay and RNAi knockdown to screen a genome-wide library of protein phosphatases for mitotic exit functions in human cells. We identify a trimeric PP2A–B55 α complex as a key factor in mitotic spindle breakdown and postmitotic reassembly of the nuclear envelope, Golgi apparatus and decondensed chromatin. Using a chemically induced mitotic exit assay, we find that PP2A–B55 α functions downstream of Cdk1 inactivation. PP2A–B55 α isolated from mitotic cells had reduced phosphatase activity towards the Cdk1 substrate, histone H1, and was hyper-phosphorylated on all subunits. Mitotic PP2A complexes co-purified with the nuclear transport factor importin- β 1, and RNAi depletion of importin- β 1 delayed mitotic exit synergistically with PP2A–B55 α . This demonstrates that PP2A–B55 α and importin- β 1 cooperate in the regulation of postmitotic assembly mechanisms in human cells.

In the budding yeast, *Saccharomyces cerevisiae*, Cdk1 substrate dephosphorylation and mitotic exit depend on the Cdc14 phosphatase⁷, but this function does not seem to be conserved in Cdc14 homologues of other species^{2,3,8–11}. Studies in cycling *Xenopus laevis* embryonic extracts suggest that phosphatases of both the PP1 (ref. 5) and PP2A (ref. 6) families

can contribute to Cdk1 substrate dephosphorylation during vertebrate mitotic exit, whereas Ca²⁺-triggered mitotic exit in cytostatic-factor-arrested egg extracts depends on calcineurin^{12,13}. Early genetic studies in *Drosophila melanogaster*^{14,15} and *Aspergillus nidulans*¹⁶ reported defects in late mitosis of PP1 and PP2A mutants. However, the assays used in these studies were not specific for mitotic exit because they scored pro-metaphase arrest or anaphase chromosome bridges, which can result from defects in early mitosis.

Intracellular targeting of Ser/Thr phosphatase complexes to specific substrates is mediated by a diverse range of regulatory and targeting subunits that associate with a small group of catalytic subunits^{3,4,17}. It is possible that mitotic exit in intact cells requires phosphatases that have not been detected by previous assays using *in vitro* extracts. In practice, the short duration of mitotic exit makes it difficult to assay this process, which explains why previous RNAi screening of cell division regulators¹⁸ did not annotate mitotic exit phenotypes.

To assay mitotic exit in live human cells, we measured the timing from anaphase onset until nuclear reformation. We generated a HeLa cell line stably expressing a chromatin marker (histone 2B fused to a red fluorescent protein; H2B–mCherry¹⁹) to visualize the metaphase–anaphase transition (Fig. 1a–c). To probe for postmitotic nuclear reassembly, we stably co-expressed a nuclear import substrate (importin- β -binding domain of importin- α fused to monomeric enhanced green fluorescent protein; IBB–eGFP²⁰), which is cytoplasmic during mitosis and co-localizes with chromatin regions after reassembly of a functional nuclear envelope (Fig. 1a, b).

To annotate mitotic exit timing automatically in time-lapse microscopy movies, we used computational methods developed in-house (CellCognition²¹). Individual cells were detected and tracked over time, and the mitotic stage of each cell was assigned based on classification of chromatin morphology (Fig. 1c). Nuclear breakdown and reassembly was

¹Institute of Biochemistry, Swiss Federal Institute of Technology Zurich (ETHZ), Schafmattstrasse 18, CH-8093 Zurich, Switzerland. ²Marine Biological Laboratory, Woods Hole, MA 02543, USA. ³Current address: Systems and Cell Biology of Neurodegeneration, Division of Psychiatry Research, University of Zurich, August Forel-Strasse 1, CH-8008 Zurich, Switzerland. ⁴Laboratory of Protein Phosphorylation and Proteomics, Department of Molecular Cell Biology, Faculty of Medicine, KU Leuven, Gasthuisberg O&N1, Herestraat 49 Box 901, B-3000 Leuven, Belgium. ⁵Institute of Molecular Pathology, Dr. Bohr-Gasse 7, 1030 Vienna, Austria. ⁶Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Dr. Bohr-Gasse 3, 1030 Vienna, Austria. ⁷Department of Cellular & Molecular Medicine and the Ottawa Institute of Systems Biology, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada. ⁸Wellcome Trust Centre for Gene Regulation & Expression, MSI/WTB/JBC Complex, University of Dundee, Dundee, DD1 5EH, UK. ⁹Max-Planck-Institute for Molecular Cell Biology and Genetics, Pfotenhauerstrasse 108, D-01307 Dresden, Germany.

¹⁰Correspondence should be addressed to D.W.G. (daniel.gerlich@bc.biol.ethz.ch)

Received 27 May 2010; accepted 02 July 2010; published online 15 August 2010; DOI: 10.1038/ncb2092




Figure 1 Live-cell imaging assay of mitotic exit timing. **(a)** Automated time-lapse microscopy imaging of a HeLa cell line stably expressing a chromatin marker (H2B-mCherry; red) and a nuclear import substrate (IBB-eGFP; green). The selected images show approximately 13% of a movie field-of-view. For full movie, see Supplementary Information, Movie S1. **(b)** Time-lapse microscopy of a single cell progressing through mitosis; onset of anaphase is marked as 0 min. **(c)** Automated detection of chromatin regions, tracking of cells over time, annotation of mitotic stages and classification of chromatin morphologies by supervised machine learning. For full movie, see Supplementary Information, Movie S2. **(d)** Automated

determined by recording changes in the ratio of mean IBB-eGFP fluorescence in chromatin regions versus surrounding cytoplasmic regions (Fig. 1d). Automated annotation of mitotic exit timing (4.70 ± 0.89 min; mean \pm s.d.) closely matched manual annotation (4.88 ± 0.84 min; mean \pm s.d.; $n = 270$ cells, Supplementary Information, Fig. S1).

Cells were transfected with 675 different siRNAs targeting a genome-wide set of 225 annotated human protein phosphatases, including catalytic and associated regulatory and scaffolding subunits (three different siRNAs per gene, two experimental replicates; for a full list of siRNAs see Supplementary Information, Table 1). These cells were then imaged over approximately 24 h with time-intervals of approximately 3.8 min. On average, this yielded approximately 87 automatically annotated mitotic

detection of nuclear breakdown and reassembly. Chromatin regions (red outline) were defined by automated segmentation of the chromatin-associated H2B-mCherry fluorescence (as shown in c). Cytoplasmic regions (green outline indicates outer boundary, red outline is inner boundary) were derived by dilation of the chromatin regions. The ratio of mean IBB-eGFP fluorescence in chromatin versus cytoplasmic regions served to automatically determine nuclear envelope breakdown (orange bar) and reformation after anaphase (nuclear import of IBB, blue bar). Anaphase onset was defined by the classification of chromatin morphology (violet bar, see c). a.u., arbitrary units. Scale bars, 10 μ m.

events per movie (total: 113,236 mitotic events). The mean mitotic exit timing was determined for all data sets that contained more than 10 mitotic events ($n = 1,278$ from 1,350 movies). Five siRNAs reproducibly scored as ‘hits’ above a significance cut-off at three standard deviations above the mean of all data points (z -score = 3; Fig. 2a). These five siRNAs targeted three distinct genes, encoding each of the three subunits of a heterotrimeric PP2A complex: PPP2CA (catalytic subunit α , subsequently labelled as CA), PPP2R1A (scaffold subunit α , subsequently labelled as R1A), and PPP2R2A (a regulatory B-type subunit, also termed PR55 α or B55 α and subsequently labelled as B55 α). The remaining four siRNAs targeting the same PP2A genes also prolonged mitotic exit, albeit below the cut-off level (Fig. 2a).




Figure 2 RNAi screen for mitotic exit regulators. **(a)** RNAi screen of a genome-wide library of annotated protein phosphatases using the mitotic exit assay shown in Figure 1. Individual data points correspond to the z-score based on the mean mitotic exit timing in individual movies, determined in two experimental replicates. Negative controls are black. siRNA oligos that resulted in phenotypes reproducibly scoring a z-score threshold of > 3 (dashed lines) were considered as hits (highlighted by colours as indicated in legend; siRNAs targeting the same genes as the hits but with z-scores below threshold are also highlighted). **(b)** RNAi depletion of B55 α in a HeLa cell line stably expressing LAP-tagged mouse-B55 α from a bacterial artificial chromosome (BAC; for localization see Supplementary Information, Fig. S6b). Cells were transfected with siRNA targeting either human B55 α alone (B55 α h), or both mouse- and human-B55 α (B55 α m/h). A quantitative western blot is shown, probed with an anti-B55 α antibody that recognizes both mouse- and human-B55 α . **(c)** Rescue of mitotic exit delay phenotype by exogenous B55 α . HeLa cells expressing mouse-B55 α -LAP were RNAi-depleted for human (h) or mouse/human (m/h) B55 α (as validated in **b**), or for the scaffolding

subunit of PP2A (R1A), and the timing of mitotic exit was then assessed. **(d)** Cumulative histograms for early mitotic progression. Nuclear envelope breakdown until anaphase onset was timed in control and RNAi-depleted HeLa cells stably expressing H2B-mCherry and IBB-eGFP (as in Figure 1; $n \geq 64$, under all conditions). **(e)** Cumulative histograms of mitotic exit. Anaphase onset until nuclear import of IBB-eGFP was measured for the same cells shown in **d**. **(f)** Synthetic depletion RNAi screen for mitotic exit phosphatases. Assay, sample preparation and siRNA library was identical to the screen shown in **a**, except that siRNA targeting B55 α was co-transfected in each experimental condition. Negative controls (black) were transfected by only non-targeting siRNA. The plot shows the ranked z-scores of a single replicate, calculated as in **a**. Dashed line indicates z-score threshold. **(g)** Time-lapse microscopy images of a cell depleted of all three PP2A-B55 α subunits progressing from anaphase through mitotic exit (as indicated by red and green bars above the images). Full movie shown in Supplementary Information, Movie S4. For negative control, see Supplementary Information, Movie S3. Scale bar, 10 μ m. Uncropped image of blot is shown in Supplementary Information, Fig. S9a.

To validate the hits, we tested an extended set of six siRNAs per gene, which all significantly prolonged mitotic exit ($P < 0.001$; Supplementary

Information, Fig. S2a–c). The mRNA depletion levels correlated with phenotypic penetrance, indicating specificity of the phenotype (Supplementary




Figure 3 PP2A-B55 α controls postmitotic Golgi assembly, spindle breakdown and chromatin decondensation. **(a)** Images from a confocal microscopy time-lapse movie of a control cell expressing H2B-mCherry and the Golgi marker, GaT-eGFP (for full movie, see Supplementary Information, Movie S5). Golgi reassembly was scored based on clustering of the fluorescence into two distinct patches per cell ($t = 9$ min). **(b)** Golgi reassembly in a PP2A-B55 α -depleted cell (for full movie, see Supplementary Information, Movie S6). **(c)** Confocal microscopy time-lapse images of mitotic spindle disassembly and chromosome decondensation in a control cell (for full movie, see Supplementary Information, Movie S7). Spindle disassembly was scored based on the first apparent detachment of spindle-pole-associated microtubules from chromatin masses ($t = 9$ min). **(d)** Mitotic spindle disassembly in a PP2A-B55 α -depleted cell (for full movie, see Supplementary Information, Movie S8). **(e, f)** Cumulative histograms of postmitotic Golgi clustering (**e**), or spindle disassembly (**f**) relative to anaphase onset ($t = 0$ min). Scale bars, 10 μ m.

Information, Fig. S2a–f). RNAi depletion was also efficient at the protein level (Supplementary Information, Fig. S2g). Next, we depleted endogenous B55 α in a HeLa cell line stably expressing eGFP-tagged mouse B55 α . Transfection of siRNA targeting a non-conserved sequence on the human B55 α mRNA efficiently depleted endogenous B55 α , but not the exogenous mouse B55 α (Fig. 2b), and these cells showed normal mitotic exit timing

(Fig. 2c). In contrast, transfection of siRNA targeting both human and mouse B55 α mRNA, or R1A, efficiently delayed mitotic exit (Fig. 2c). This provides validation that on-target depletion of B55 α mRNA causes the observed mitotic exit phenotype.

The PP2A protein phosphatase family is involved in many cellular processes, including earlier mitotic stages³. It is generally accepted that the regulatory B-type subunit confers substrate specificity and thereby regulates diverse functions of PP2A^{3,17}. Depletion of CA or R1A significantly prolonged mitotic progression from nuclear envelope breakdown until anaphase ($P < 0.001$; Fig. 2d; same cells shown in Fig. 2e), as expected from the known functions of PP2A complexes in spindle assembly and chromosome cohesion (which involve other B-type subunits³). In contrast, early mitotic progression was unaffected in B55 α -depleted cells. These data indicate that PP2A function is required at all stages of mitosis, whereas the B55 α subunit is rate-limiting only for post-anaphase progression.

Depletion of PP2A-B55 α subunits delayed, but did not arrest, mitotic exit (Fig. 2e). This may be explained by incomplete RNAi depletion or the involvement of other unknown factors with redundant function. To investigate if additional phosphatases become limiting in the absence of B55 α , we screened the phosphatase-targeting siRNA library in a background of synthetic B55 α RNAi depletion. Increased mitotic exit delay occurred upon co-depletion of R1A or CA subunits with B55 α (2–3 oligos scoring above a z-score threshold of 3; Fig. 2f). However, none of the other 222 phosphatases showed a consistent additive increase in mitotic exit delay (five other siRNA oligos delayed slightly above the z-score threshold, but could not be confirmed by different siRNAs targeting the same genes). Co-transfection of siRNAs targeting all three PP2A-B55 α subunits (labelled as PP2A-B55 α siRNA throughout the manuscript) caused the most pronounced prolongation of mitotic exit (14.76 ± 6.50 min, $n = 205$ versus 4.86 ± 1.07 min in the control, $n = 251$; mean \pm s.d.; Fig. 2g and Supplementary Information, Fig. S2g). The additive effect of combinatorial PP2A-B55 α subunit depletions suggests that residual levels of this phosphatase may account for a slow and gradual mitotic exit. The fact that no other RNAi conditions further delayed mitotic exit in combination with B55 α depletion underlines the particular importance of PP2A-B55 α for mitotic exit.

To address if PP2A-B55 α controls postmitotic reassembly of cellular structures other than the nucleus, we generated a HeLa cell line stably expressing a fluorescent Golgi marker (galactosyl transferase, GaT-eGFP²²) and H2B-mCherry (Fig. 3a). Time-lapse confocal microscopy showed that depletion of the PP2A-B55 α complex significantly delayed postmitotic clustering of Golgi fragments ($P < 0.001$; 25.5 ± 5.86 min, $n = 31$ versus 11.17 ± 2.73 min in the control, $n = 30$; mean \pm s.d.; Fig. 3a, b, e and see Supplementary Information, Fig. S3b, c for single depletion of B55 α). In another mitotic exit assay, we imaged a HeLa cell line stably expressing H2B-mCherry and eGFP- α -tubulin¹⁹ (Fig. 3c). PP2A-B55 α -depleted cells showed significantly delayed disassembly of spindle-pole-associated microtubules ($P < 0.001$; Fig. 3c, d, f). Postmitotic chromosome decondensation was also significantly delayed in PP2A-B55 α -depleted cells ($P < 0.001$; 18.29 ± 2.29 min, $n = 98$ versus 8.94 ± 5.89 min in the control, $n = 158$; mean \pm s.d.; see also Supplementary Information, Fig. S3d). These data show that PP2A-B55 α contributes to postmitotic reassembly of various interphase cell structures.

We next investigated how depletion of PP2A-B55 α affects progression through interphase, using a monoclonal cell line expressing




Figure 4 PP2A-B55 α functions downstream of Cdk1 inactivation. **(a)** Experimental protocol for observation of mitotic exit induced by chemical inactivation of Cdks in absence of proteasome-mediated degradation. MG132 is the proteasome inhibitor and flavopiridol is the Cdk inhibitor. **(b, c)** Time-lapse microscopy images of cells expressing H2B-mCherry and IBB-eGFP. A control cell is shown in **b** (for full movie, see Supplementary Information, Movie S9) and a cell transfected with siRNA targeting PP2A-B55 α is shown in **c** (for full movie, see Supplementary Information, Movie S10). Dashed red line indicates addition of flavopiridol, green bar indicates onset of IBB-eGFP nuclear import. **(d, e)** Golgi reassembly after chemically induced mitotic exit in cells expressing H2B-mCherry and the Golgi marker, GaIT-eGFP. A control cell is shown in **d** and a cell transfected

with siRNA targeting PP2A-B55 α is shown in **e**. Dashed red line indicates addition of flavopiridol, green bar indicates onset of Golgi clustering. **(f, g)** Cumulative histograms of nuclear reassembly timing (**f**) and Golgi reassembly timing (**g**) based on the data shown in **b–e**. **(h)** Detection of Cdk1 substrate phosphorylation by an anti-phosphorylated-Ser antibody that specifically recognizes the Cdk target sequence K/R-pS-P-X-K/R (where X is any residue and pS is phosphorylated Ser) on a western blot. Samples were prepared after chemical induction of mitotic exit in synchronized cells in presence of proteasome inhibitor as in **a**. In control cells, Cdk substrates dephosphorylate rapidly (Control siRNA, lanes 1–7). Cells depleted for PP2A-B55 α show delayed dephosphorylation (lanes 8–14). Scale bars, 10 μ m. Uncropped image of blot is shown in Supplementary Information, Fig. S9b.

H2B-mCherry and a DNA replication marker (proliferating cell nuclear antigen) tagged with enhanced GFP (eGFP-PCNA²³; Supplementary Information, Fig. S4a–d). PP2A-B55 α -depleted cells had a prolonged G1 phase (10.49 ± 2.70 h, $n = 31$ versus 5.77 ± 1.11 h in the control, $n = 39$; mean \pm s.d.; Supplementary Information, Fig. S4b), as expected after perturbation of mitotic exit. Conversely, PP2A-B55 α -depleted cells had a significantly shorter G2 phase ($P < 0.001$; 2.91 ± 0.39 h, $n = 42$ versus 3.95 ± 0.78 h in the control, $n = 37$; mean \pm s.d.; Supplementary Information, Fig. S4d). This is consistent with previous observations in *Xenopus* embryonic extracts^{6,24}.

The mitotic exit phenotypes observed after PP2A-B55 α depletion could be caused by a failure in Cdk1 inactivation, misregulated Cdk1 substrate dephosphorylation or both. To discriminate between these possibilities, we established a mitotic exit assay using chemical inactivation of Cdk1. Cells were first arrested in metaphase by the proteasome inhibitor MG132 and then forced to exit from mitosis by adding the Cdk inhibitor flavopiridol (still in the presence of MG132) to a final concentration of 20 μ M (ref. 25; Fig. 4a). This treatment promoted changes that are indicative of mitotic exit, including nuclear reassembly (> 95% of all metaphase cells, $n = 99$), Golgi clustering (> 90%, $n = 103$), chromosome decondensation and re-attachment to the substratum (Fig. 4b, d). Only chromosome

segregation did not occur, probably owing to the suppression of securin degradation by MG132. Higher concentrations of flavopiridol did not further accelerate nuclear reassembly (9.4 ± 1.1 min at 160 μ M, $n = 30$ compared with 9.3 ± 1.3 min at 20 μ M, $n = 30$; mean \pm s.d.), indicating that Cdk1 inhibition was complete. PP2A-B55 α depletion significantly delayed nuclear reassembly in this assay ($P < 0.001$; 20.67 ± 3.30 min, $n = 41$ versus 9.86 ± 0.95 min in the control, $n = 29$; mean \pm s.d.; Fig. 4b, c, f and see Supplementary Information, Fig. S5a–c for single depletion of B55 α). Golgi reformation was also delayed (36.01 ± 9.38 min, $n = 35$ versus 16.91 ± 2.27 min in the control, $n = 42$; mean \pm s.d.; Fig. 4d, e, g). We conclude that a main function of PP2A-B55 α in promoting mitotic exit must be downstream of Cdk1 inactivation.

To test if PP2A-B55 α depletion affected dephosphorylation of Cdk1 substrates, extracts were prepared from HeLa cells synchronized to different times after chemical induction of mitotic exit. Cdk1 substrate phosphorylation, detected on quantitative western blots by an anti-phosphorylated-Ser antibody that specifically recognizes the Cdk target sequence K/R-pS-P-X-K/R (where X is any residue and pS is phosphorylated Ser), dropped to approximately 23% within 18 min of flavopiridol addition in control cells, whereas it remained at approximately 66% in PP2A-B55 α -depleted cells (Fig. 4h and see Supplementary Information,





Figure 5 Cell-cycle-dependent regulation of PP2A–B55 α . **(a, b)** PP2A–B55 α , isolated from nocodazole-treated mitotic (M) or unsynchronized interphase (I) by pulldown of GST–B55 α , was assayed for **(a)** phosphatase activity towards Cdk1–cyclin B-phosphorylated histone H1 ($n = 15$; values indicate means \pm s.d., asterisks denote $P < 0.001$; values normalized to interphase cells) and **(b)** activity towards its substrate, phosphorylase a ($n = 3$; values normalized to interphase cells). **(c)** Purification of PP2A complexes from interphase (I) or mitotic (M) HeLa cells stably expressing LAP-tagged R1A or B55 α baits, resolved by SDS–PAGE and silver staining. Two mitosis-specific bands were identified by mass spectrometry: importin- β 1 (1), and importin- α 1 (2). Expected positions of the bands from endogenous PP2A subunits are indicated on the right and migration positions of mouse baits are marked with asterisks. **(d)** PP2A complexes were purified with R1A-LAP by immunoprecipitation and resolved on a western blot by probing with anti-R1A and anti-importin- β 1 antibodies. **(e)** Importin- β 1 function in mitotic exit. Cells expressing H2B-mCherry and GalT-eGFP were transfected with siRNAs as indicated. Timing from anaphase ($t = 0$ min) until Golgi reassembly was assayed as in Fig. 3 ($n \geq 30$ for each condition). **(f)** Phosphorylation sites on PP2A–B55 α were identified by mass spectrometry and are highlighted in red on the 3D structure of PP2A–B55 α ³⁴ and in the associated primary sequences. The abundance of phosphorylated peptide in the mitotic sample was estimated by peak area quantification of the elution profiles and is indicated as percentage of total peptide based on elution profile peak area normalization. Mitotic phosphorylation increase (indicated in brackets) was estimated by comparing the normalized peak area quantifications of phosphorylated peptides in interphase with mitotic samples. **(g)** Phosphorylation of B55 α Ser 167 affects PP2A complex assembly. GST-tagged wild-type-B55 α or GST-tagged substitution mutants of B55 α (a non-phosphorylatable S167A mutant or a phospho-mimicking S167E mutant) were isolated from unsynchronized (I) or mitotic (M) cells by GST-pulldown. PP2A subunits were detected on western blots by anti-GST, anti-R1A and anti-CA antibodies.



on the 3D structure of PP2A–B55 α ³⁴ and in the associated primary sequences. The abundance of phosphorylated peptide in the mitotic sample was estimated by peak area quantification of the elution profiles and is indicated as percentage of total peptide based on elution profile peak area normalization. Mitotic phosphorylation increase (indicated in brackets) was estimated by comparing the normalized peak area quantifications of phosphorylated peptides in interphase with mitotic samples. **(g)** Phosphorylation of B55 α Ser 167 affects PP2A complex assembly. GST-tagged wild-type-B55 α or GST-tagged substitution mutants of B55 α (a non-phosphorylatable S167A mutant or a phospho-mimicking S167E mutant) were isolated from unsynchronized (I) or mitotic (M) cells by GST-pulldown. PP2A subunits were detected on western blots by anti-GST, anti-R1A and anti-CA antibodies. **(h)** Model for mitotic exit control. Dephosphorylation of a broad range of mitotic Cdk1 substrates promotes reassembly of interphase cells during mitotic exit. A balance of kinase (Cdk1–cyclin B) and phosphatase (PP2A–B55 α) activities determines the substrate dephosphorylation kinetics during mitotic exit. Green indicates activated state, red indicates lower activity and P indicates phosphorylation. Uncropped images of blot are shown in Supplementary Information, Fig. S9c.

Fig. S5e for single depletion of B55 α). This supports the conclusion that PP2A–B55 α functions downstream of Cdk inactivation during mitotic exit and shows that PP2A–B55 α is required for timely Cdk1 substrate dephosphorylation.

Previous studies in *Xenopus* embryonic extracts^{5,13} and HeLa cells²⁶ have indicated that there is reduced phosphatase activity towards Cdk1 targets during early mitosis. Human PP2A–B55 α isolated from mitotic cells had significantly reduced activity towards Cdk1-phosphorylated histone H1 ($P < 0.001$; $71 \pm 15\%$ versus $100 \pm 11\%$ in interphase; mean \pm s.d., $n = 15$; Fig. 5a). However, we did not detect any cell cycle-dependent differences in the phosphatase activity towards another well-characterized model substrate, phosphorylase a (Fig. 5b). This suggests cell cycle-regulated changes of PP2A–B55 α substrate specificity.

All three PP2A–B55 α subunits were expressed at similar levels in interphase and mitosis (Supplementary Information, Fig. S6a), indicating that mitotic PP2A–B55 α is unlikely to be regulated at the protein level. We addressed potential changes in PP2A complex composition at different cell cycle stages by purification of LAP (localization and affinity purification)-tagged R1A or B55 α , stably expressed from endogenous promoters²⁷. R1A co-purified with several mitosis-specific binding partners (Fig. 5c), two of which were identified by mass spectrometry as the nuclear transport factors, importin- α 1 and importin- β 1. In addition to a function in nuclear transport during interphase, importin- β 1 is part of a mitotic regulatory system involving the small GTPase Ran, which is known to control mitotic spindle and nuclear envelope assembly²⁸. After validation of the mitosis-specific interaction between importin- β 1 and R1A by western blotting (Fig. 5d), we investigated if importin- β 1 contributes to mitotic exit progression. Because the specificity of the nuclear reassembly assay may be compromised after depletion of a nuclear import factor, we assayed mitotic exit by monitoring Golgi reformation. Importin- β 1 depletion (Supplementary Information, Fig. S2h, i) significantly delayed post-mitotic Golgi reassembly ($P \leq 0.001$; 14.7 ± 5.0 min, $n = 30$ versus 10.1 ± 1.4 min in the control, $n = 30$; mean \pm s.d.; Fig. 5e), which was further increased after co-transfection of siRNAs targeting R1A or B55 α (25.9 ± 6.3 min, $n = 30$ and 22.5 ± 8.1 min, $n = 25$, respectively). Importin- β 1 depletion also prolonged earlier mitotic stages (Supplementary Information, Fig. S7), as expected from its known function in spindle assembly. These data demonstrate that PP2A–B55 α and importin- β 1 jointly promote mitotic exit.

By mass spectrometry, we detected five phosphorylation sites on the PP2A complex purified from mitotic cells (Fig. 5f). The relative quantities of phosphorylated peptides were estimated by a semi-quantitative approach, using the extracted ion chromatogram for peak area quantification of the peptide elution profiles (Supplementary Information, Fig. S8). Phosphorylation of B55 α at Ser 167 was estimated to be highly abundant at 55% (mean; $n = 2$ independent experiments), whereas the other sites were phosphorylated on < 1% of the eluted peptides (quantifications provided in Fig. 5f; the phosphorylation levels of S8 on R1A could not be determined because no unmodified peptides containing this site were detected). PP2A is known to auto-dephosphorylate²⁹, therefore the absolute phosphorylation levels in cells may be higher. All four of the quantified phosphorylations were enriched more than fivefold on PP2A purified from mitotic cells (Fig. 5f; Supplementary Information, Fig. S8). To test if PP2A complex assembly is regulated by the phosphorylation of

B55 α at Ser 167, we isolated PP2A complexes from interphase and mitotic HeLa cells by expression of a GST (glutathione S-transferase)-tagged B55 α phospho-mimicking S167E mutant. Indeed, the S167E mutant bound less efficiently to the CA and R1A subunits, compared with wild-type B55 α or a non-phosphorylatable S167A mutant (Fig. 5g and Supplementary Information, Fig. S9h).

This study provides a comprehensive screen for mitotic exit phosphatases in human cells. B55 α has been previously shown to increase PP2A activity towards Cdk1 phosphorylation sites³⁰, consistent with the possibility that PP2A–B55 α promotes mitotic exit by direct dephosphorylation of Cdk1 substrates. The *in vitro* phosphatase activity of mitotic PP2A–B55 α towards Cdk1-phosphorylated H1 was downregulated. However, it is not known which of the many putative PP2A substrates may be affected by this regulation, and therefore we cannot precisely estimate the extent to which PP2A regulation shapes the kinetics of Cdk1 substrate dephosphorylation.

Our data raise interesting possibilities for PP2A regulatory mechanisms (Fig. 5h). A B55 α phospho-mimicking S167E mutation impaired the binding of R1A and CA subunits, consistent with the possibility that phosphorylation contributes to a cell cycle-dependent regulation of PP2A–B55 α complex assembly. This may also involve mitotic hyperphosphorylation of the CA subunit at Thr 304, as a previous study showed that a phospho-mimicking T304D mutation also suppresses assembly of B55 α into PP2A complexes³¹. Importin- β 1 may regulate PP2A by direct binding, by a nuclear-cytoplasmic targeting mechanism or as a molecular chaperone²⁸. In this context, it is interesting to note that importin- β 1 is structurally related to the R1A subunit and members of the B' family of regulatory PP2A subunits³². Even though it is possible that importin- β 1 functions in a mitotic exit pathway independently of PP2A, the physical and functional interaction observed here suggests a link between the importin-/Ran and Cdk1-phosphorylation regulatory systems.

In contrast to the *Xenopus* embryonic extract system⁶, depletion of B55 δ in HeLa cells (down to 20% mRNA level; Supplementary Information, Fig. S2j) did not delay mitotic exit. This may reflect different relative expression levels of the B55-subfamily isoforms in the two systems or technical limitations of the depletion methods. A previous study proposed that PP1 dominates as a Cdk1-counteracting phosphatase in cycling *Xenopus* embryonic extracts⁵. The fact that we did not detect mitotic exit delays after RNAi depletion of any of the PP1 catalytic or regulatory subunits may be related to the cellular context of our phenotypic assays instead of homogenized extracts or to differences between embryonic and somatic mitosis. However, potential functional redundancy between different PP1 catalytic isoforms that were targeted only individually in our screen may have masked phenotypes; therefore we cannot rule out the possibility that PP1 also contributes to mitotic exit in human somatic cells.

In conclusion, our study reveals PP2A–B55 α and importin- β 1 as key regulators of cellular reassembly mechanisms during mitotic exit. Mitotic exit has been recently recognized as a target for improved, next-generation cancer therapeutics³³. B55 α and importin- β 1 are therefore good targets for the development of mitotic exit-specific inhibitors. □

METHODS

Methods and any associated references are available in the online version of the paper at <http://www.nature.com/naturecellbiology/>

Note: Supplementary Information is available on the *Nature Cell Biology* website

ACKNOWLEDGMENTS

The authors thank F. Uhlmann and B. Novak for critical comments on the manuscript. We thank S. Maar, the ETHZ Light Microscopy Centre (LMC), the ETHZ RNAi Screening Centre (RISC), M. Augsburg (The Max Planck Institute of Molecular Cell Biology and Genetics; MPI-CBG), M. Leuschner (MPI-CBG) and A. Ssykor (MPI-CBG) for technical assistance. We thank U. Kutay (ETHZ) for anti-importin- β 1 and anti-nucleolin antibodies, J. Rohrer (University of Zurich) for providing GalT-eGFP plasmid, J. Ellenberg (EMBL, Heidelberg) for IBB-eGFP plasmid, M.C. Cardoso (Technical University, Darmstadt) for eGFP-PCNA plasmid and Sanofi Aventis and the National Cancer Institute for providing flavopiridol. This work was supported by Swiss National Science Foundation (SNF) research grant 3100A0-114120, SNF ProDoc grant PDFMP3_124904, a European Young Investigator (EURIYI) award of the European Science Foundation to D.W.G., a MBL Summer Research Fellowship by the Evelyn and Melvin Spiegel Fund to D.W.G., a Roche Ph.D. fellowship to M.H.A.S. and a Mueller fellowship of the Molecular Life Sciences Ph.D. programme Zurich to M.H. M.H. and M.H.A.S. are fellows of the Zurich Ph.D. programme in Molecular Life Sciences. V.J. and J.G. were supported by grants of the 'Geconcerdeerde OnderzoeksActies' of the Flemish government, the 'Interuniversity Attraction Poles' of the Belgian Science Policy P6/28 and the 'Fonds voor Wetenschappelijk Onderzoek-Vlaanderen'. A.I.L. is a Wellcome Trust Principal Research Fellow. A.A.H. acknowledges funding by the Max Planck Society, MitoCheck (the EU-FP6 integrated project), and a BMBF (Bundesministerium für Bildung und Forschung) grant, DiGtoP (01GS0859). Work in the groups of K.M. and J.M.P. was supported by MitoCheck (the EU-FP6 integrated project), Boehringer Ingelheim, the GEN-AU programme of the Austrian Federal Ministry of Science and Research (Austrian Proteomics Platform III), MeioSys within the Seventh Framework Programme of the European Commission and by Chromosome Dynamics, which is funded by the Austrian Science Foundation (FWF).

AUTHOR CONTRIBUTIONS

M.H.A.S. performed all experiments, except the mass spectrometry and *in vitro* phosphatase assays, and wrote part of the paper. M.H. implemented software for automated imaging and data analysis. V.J., E.I. and J.G. performed *in vitro* phosphatase assays and B55 α phospho-mutant analysis. J.H. and J.M.P. designed and performed PP2A purification. K.M. and O.H. performed mass spectrometry. L.T.M. and A.I.L. compiled the phosphatase screening library. I.P. and A.A.H. generated the cell lines stably expressing LAP-tagged PP2A subunits. D.W.G. conceived the project, designed the screening strategy and wrote the paper.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Published online at <http://www.nature.com/naturecellbiology>

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions/>

1. Morgan, D. O. *The cell cycle: principles of control*. (Oxford University Press, 2007).
2. Queralt, E. & Uhlmann, F. Cdk-counteracting phosphatases unlock mitotic exit. *Curr. Opin. Cell Biol.* **20**, 661–668 (2008).
3. Bollen, M., Gerlich, D. W. & Lesage, B. Mitotic phosphatases: from entry guards to exit guides. *Trends Cell Biol.* **19**, 531–541 (2009).
4. Trinkle-Mulcahy, L. & Lamond, A. I. Mitotic phosphatases: no longer silent partners. *Curr. Opin. Cell Biol.* **18**, 623–631 (2006).
5. Wu, J. Q. et al. PP1-mediated dephosphorylation of phosphoproteins at mitotic exit is controlled by inhibitor-1 and PP1 phosphorylation. *Nat. Cell Biol.* **11**, 644–651 (2009).
6. Mochida, S., Ikeo, S., Gannon, J. & Hunt, T. Regulated activity of PP2A-B55 δ is crucial for controlling entry into and exit from mitosis in *Xenopus* egg extracts. *EMBO J.* **28**, 2777–2785 (2009).

7. Stegmeier, F. & Amon, A. Closing mitosis: the functions of the Cdc14 phosphatase and its regulation. *Annu. Rev. Genet.* **38**, 203–232 (2004).
8. Berdugo, E., Nachury, M. V., Jackson, P. K. & Jallepalli, P. V. The nucleolar phosphatase Cdc14B is dispensable for chromosome segregation and mitotic exit in human cells. *Cell Cycle* **7**, 1184–1190 (2008).
9. Gruneberg, U., Glotzer, M., Gartner, A. & Nigg, E. A. The CeCDC-14 phosphatase is required for cytokinesis in the *Caenorhabditis elegans* embryo. *J. Cell Biol.* **158**, 901–914 (2002).
10. Mailand, N. et al. Deregulated human Cdc14A phosphatase disrupts centrosome separation and chromosome segregation. *Nat. Cell. Biol.* **4**, 317–322 (2002).
11. Mocciaro, A. et al. Vertebrate cells genetically deficient for Cdc14A or Cdc14B retain DNA damage checkpoint proficiency but are impaired in DNA repair. *J. Cell Biol.* **189**, 631–639 (2010).
12. Nishiyama, T., Yoshizaki, N., Kishimoto, T. & Ohsumi, K. Transient activation of calcineurin is essential to initiate embryonic development in *Xenopus laevis*. *Nature* **449**, 341–345 (2007).
13. Mochida, S. & Hunt, T. Calcineurin is required to release *Xenopus* egg extracts from meiotic M phase. *Nature* **449**, 336–340 (2007).
14. Mayer-Jaekel, R. E. et al. The 55 kDa regulatory subunit of *Drosophila* protein phosphatase 2A is required for anaphase. *Cell* **72**, 621–633 (1993).
15. Axton, J. M., Dombradi, V., Cohen, P. T. & Glover, D. M. One of the protein phosphatase 1 isoenzymes in *Drosophila* is essential for mitosis. *Cell* **63**, 33–46 (1990).
16. Doonan, J. H. & Morris, N. R. The *bimG* gene of *Aspergillus nidulans*, required for completion of anaphase, encodes a homolog of mammalian phosphoprotein phosphatase 1. *Cell* **57**, 987–996 (1989).
17. Janssens, V., Longin, S. & Goris, J. PP2A holoenzyme assembly: *in cauda venenum* (the sting is in the tail). *Trends Biochem. Sci.* **33**, 113–121 (2008).
18. Neumann, B. et al. Phenotypic profiling of the human genome by time-lapse microscopy reveals cell division genes. *Nature* **464**, 721–727 (2010).
19. Steigemann, P. et al. Aurora B-mediated abscission checkpoint protects against tetraploidization. *Cell* **136**, 473–484 (2009).
20. Dultz, E. et al. Systematic kinetic analysis of mitotic dis- and reassembly of the nuclear pore in living cells. *J. Cell Biol.* **180**, 857–865 (2008).
21. Held, M. et al. CellCognition: time-resolved phenotype annotation in high-throughput live cell imaging. *Nat. Methods* doi: 10.1038/nmeth.1486 (in the press).
22. Schaub, B. E., Berger, B., Berger, E. G. & Rohrer, J. Transition of galactosyltransferase 1 from *trans*-Golgi cisterna to the *trans*-Golgi network is signal mediated. *Mol. Biol. Cell* **17**, 5153–5162 (2006).
23. Leonhardt, H. et al. Dynamics of DNA replication factories in living cells. *J. Cell Biol.* **149**, 271–280 (2000).
24. Lee, T. H., Turck, C. & Kirschner, M. W. Inhibition of cdc2 activation by INH/PP2A. *Mol. Biol. Cell* **5**, 323–338 (1994).
25. Potapova, T. A. et al. The reversibility of mitotic exit in vertebrate cells. *Nature* **440**, 954–958 (2006).
26. Skoufias, D. A., Indorato, R. L., Lacroix, F., Panopoulos, A. & Margolis, R. L. Mitosis persists in the absence of Cdk1 activity when proteolysis or protein phosphatase activity is suppressed. *J. Cell Biol.* **179**, 671–685 (2007).
27. Poser, I. et al. BAC TransgeneOmics: a high-throughput method for exploration of protein function in mammals. *Nat. Methods* **5**, 409–415 (2008).
28. Harel, A. & Forbes, D. J. Importin- β : conducting a much larger cellular symphony. *Mol. Cell* **16**, 319–330 (2004).
29. Guo, H. & Damuni, Z. Autophosphorylation-activated protein kinase phosphorylates and inactivates protein phosphatase 2A. *Proc. Natl. Acad. Sci. USA* **90**, 2500–2504 (1993).
30. Mayer-Jaekel, R. E. et al. *Drosophila* mutants in the 55 kDa regulatory subunit of protein phosphatase 2A show strongly reduced ability to dephosphorylate substrates of p34cdc2. *J. Cell Sci.* **107**, 2609–2616 (1994).
31. Longin, S. et al. Selection of protein phosphatase 2A regulatory subunits is mediated by the C terminus of the catalytic Subunit. *J. Biol. Chem.* **282**, 26971–26980 (2007).
32. Shi, Y. Serine/threonine phosphatases: mechanism through structure. *Cell* **139**, 468–484 (2009).
33. Huang, H. C., Shi, J., Orth, J. D. & Mitchison, T. J. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. *Cancer Cell* **16**, 347–358 (2009).
34. Xu, Y., Chen, Y., Zhang, P., Jeffrey, P. D. & Shi, Y. Structure of a protein phosphatase 2A holoenzyme: insights into B55-mediated Tau dephosphorylation. *Mol. Cell* **31**, 873–885 (2008).

METHODS

Cell lines and plasmids. The HeLa Kyoto cell line was obtained from S. Narumiya (Kyoto University, Japan) and cultured in Dulbecco's modified eagle medium (DMEM; GIBCO) supplemented with 10% (v/v) foetal bovine serum (PAA Laboratories) and 1% (v/v) penicillin–streptomycin (Invitrogen). All live-cell imaging experiments were performed using monoclonal reporter cell lines that were generated as previously described³⁵. For a complete list of plasmids and cell lines see Supplementary Information, Tables S3 and S4. Cells were grown either in 96-well microtitre plates (Greiner) or on LabTek chambered coverslips (Nunc) for live-cell microscopy. Live-cell imaging was performed in DMEM containing 10% (v/v) foetal calf serum and 1% (v/v) penicillin–streptomycin, but without phenol red and riboflavin to reduce autofluorescence of the medium³⁵.

The bacterial artificial chromosomes (BACs), RP24-103C16, harbouring mouse PP2A-B55α (PPP2R2A), and RP24-255O20, harbouring mouse PPP2CA, were obtained from the BACPAC Resources Center (<http://bacpac.chori.org>). The LAP (eGFP–IRES (internal ribosome entry site)–neomycin) cassette was PCR amplified using primers that contain 50 nucleotides homologous to the carboxy terminus of each of the target genes. Recombineering and stable transfection of the modified BAC was performed as previously described²⁷.

Live-cell imaging. Automated microscopy with reflection-based laser autofocus was performed on a Molecular Devices ImageXpress Micro screening microscope equipped with a $\times 10$, 0.5 N.A. S Fluor dry objective (Nikon), controlled by Metamorph macros developed in-house²¹. Cells were maintained in a microscope stage incubator at 37 °C in a humidified atmosphere of 5% CO₂ throughout the experiment. Illumination was adjusted so that the cell death rate was below 5% in untreated control cells. Confocal microscopy was performed on a customized Zeiss LSM 510 Axiovert microscope using a $\times 20$, 0.8 N.A. Plan-Apochromat dry objective, a $\times 40$, 1.3 N.A. oil DIC EC Plan-Neofluar objective, or a $\times 63$, 1.4 N.A. oil Plan-Apochromat objective (Zeiss). The microscope was equipped with piezo focus drives (piezosystem jena), custom-designed filters (Chroma) and an EMLB incubation chamber (European Molecular Biology Laboratory), which provided a humidified atmosphere at 37 °C with 5% CO₂.

For imaging chemically induced mitotic exit, cells were seeded in chambered LabTek coverslips overnight and then transfected with the indicated siRNAs. After transfection (52 h), the medium was replaced with imaging medium containing 30 μM MG132 (proteasome inhibitor; Sigma). The chambered coverslips were placed into the microscope stage incubator, which was maintained at 37 °C in a humidified atmosphere of 5% CO₂, for 45 min, when imaging locations with metaphase-arrested cells were selected. These cells were imaged for 10–15 min, before mitotic exit was induced with 20 μM flavopiridol (Cdk inhibitor)²⁵.

Image analysis and statistical analysis. Automated image analysis was performed by CellCognition software, which was developed in-house²¹ (<http://www.cellcognition.org>). Cell nuclei and mitotic chromosome masses were detected by local adaptive thresholding. Cytoplasmic regions were derived by region-growing the chromatin segmentation to a fixed size. Next, texture and shape features were calculated for each object and samples for mitotic classes were manually annotated for supervised classification. Support vector machine classification was performed by radial-based kernel and probability estimates. Cells were tracked over time using a constrained nearest-neighbour approach, with an algorithm that supported trajectory splitting and merging. Mitotic events were detected in the graph structure on the basis of the transition from prophase to prometaphase. Nuclear envelope reassembly was defined as an increase in the ratio of the mean nuclear versus cytoplasmic IBB–eGFP fluorescence > 1.5-fold above the ratio at the time of chromosome segregation. In the RNAi screen, mean mitotic exit timing was normalized per 96-well plate to compensate for slight differences in the temporal sampling rate. z-scores were calculated based on the mean and standard deviation of all data points. All statistical testing was by a two-tailed Student's *t*-test.

RNAi. The human siRNA phosphatase library was based on version V3.0 from Qiagen and complemented with custom siRNAs targeting missing phosphatases. For a complete list of siRNA oligos see Supplementary Information, Tables S1 and S2. RNAi duplexes were transfected in liquid phase with either Oligofectamine (Invitrogen) or HiPerfect (Qiagen) according to the manufacturer's instructions. Final siRNA concentrations were 50 nM for Oligofectamine or 10 nM for

HiPerfect. Cells were reverse transfected in 96-well microtitre plates and incubated for approximately 40 h before imaging.

Quantitative real-time PCR. mRNA was extracted from cells 40 h after transfection of siRNAs using the TurboCapture 8 mRNA Kit (Qiagen) and cDNA was prepared using random hexamer primers (Microsynth) and Ready-To-Go You-Prime First-Strand beads (GE Healthcare). Real-time PCR was performed using the LightCycler 480 SYBR Green I Master system (Roche Diagnostics). Primers were designed using AutoPrime software (www.autoprime.de) or Clone Manager. Primer pairs for the indicated genes were: CA (5'-GGAGCTGGTTACACCTTG-3' and 5'-CCAGTTATATCCCTCCATCAC-3'), RIA (5'-CTTCAATGTGGCCAAGTCTC-3' and 5'-TCTAGGATGGGCTTGACTTC-3'), B55α (5'-ATTGGGCTATGTG-ACATGAG-3' and 5'-GACCTGTTACTGGGATCTTC-3'), B55δ (5'-CTGAAAGACGAAGATGGAAG-3' and 5'-AATATTGGGACCCGTAGC-3'), importin-β1 (5'-CAGATACG AGGGTACGAGTG-3' and 5'-TTTCATTGCTTC-GATTGTG-3') and GAPDH (5'-CGTGTCACTGGTGGACCTGACC-3' and 5'-CTGCTTCAACCACCTTCTGATGTCA-3').

Protein blotting. Pelleted cells were washed with PBS and total protein lysates prepared in lysis buffer (50 mM Tris at pH 7.5, 150 mM NaCl, 1% (v/v) Nonidet P-40, 10% (v/v) glycerol and 2 mM EDTA), supplemented with Mini-Complete protease inhibitor tablet (Roche), and 20 mM β-glycerophosphate. Protein concentrations were determined using a BCA kit (Pierce). The following primary antibodies were used: polyclonal rabbit-anti-PPP2CA (1:2,000, Cell Signaling), polyclonal rabbit-anti-PPP2R1A (1:2,000, Cell Signaling), monoclonal mouse-anti-PP2A-B55α (1:500, Santa Cruz), polyclonal rabbit-anti-phosphorylated-Ser Cdk substrates (1:1,000, Cell Signaling), monoclonal mouse-anti-cyclin B1 (1:5,000, Santa Cruz) and monoclonal mouse-anti-actin (1:50,000, Millipore).

For the chemically induced mitotic exit assay, nocodazole-arrested cells (100 ng ml⁻¹ for 17 h; Sigma) were incubated for 30 min in 30 μM MG132 (Sigma), collected by shake-off, washed in PBS containing MG132 and resuspended in 800 μl of PBS (containing MG132). This suspension was divided into 100 μl aliquots in 1.5 ml centrifugation tubes at 37 °C. Mitotic exit was induced by adding flavopiridol to a final concentration of 20 μM (provided by the National Cancer Institute with permission by Sanofi-aventis). Cell aliquots were lysed at 3 min intervals over 18 min by adding 5× concentrated SDS (sodium dodecyl sulphate) cracking buffer to the respective aliquot, and boiling it for 5 min at 95 °C. Quantitative western blotting was performed using the Odyssey system (LICOR) or the FluorChem system (Alpha Innotec).

Immunoprecipitation and GST pulldowns. Subconfluent HeLa Kyoto cells expressing GST-B55α were untreated or arrested in mitosis with nocodazole (100 ng ml⁻¹ for 16 h; M). Following collection by scraping (untreated cells) or shake off (cells arrested in mitosis), cells were washed in PBS, pooled and lysed in 1 ml NET buffer (50 mM Tris at pH 7.4, 150 mM NaCl, 1% (w/v) Nonidet P-40 and 15 mM EDTA), supplemented with Mini-Complete protease inhibitors (Roche) and, when appropriate, with phosphatase-inhibitor tablet (Roche). Equal amounts of the cleared lysates (as measured using the BCA kit; Pierce) were added to 25 μl of glutathione-Sepharose (GE Healthcare) and allowed to bind for 1 h at 4 °C. As previously shown³¹, this method allows isolation of catalytically competent PP2A-B55α trimers. After four washes in NENT-100 (ref. 31) and one wash in PP2A assay buffer (20 mM Tris at pH 7.4 and 5 mM DTT; dithiothreitol), PP2A assay buffer was added to the beads for phosphatase assays on two different substrates (histone H1 and phosphorylase a) for at least two times and with three replicates for each measurement (final volume 100–120 μl). A small aliquot was used for western blotting with anti-C and anti-A (monoclonals, 1:2,000 dilution, S. Dilworth) and anti-GST antibodies (1:10,000 dilution, Sigma) to check for equal input.

Phosphatase assays. Histone H1 (6 μg; Roche) was phosphorylated by Cdk1–cyclin B1 (Biaffin) or Cdk2–cyclin A³⁶ in the presence of ³²P-labelled ATP (GE Healthcare) to a level of 5–7 moles per mole of histone. ³²P-radiolabelled histone H1 was precipitated in 25% (v/v) trichloroacetic acid (TCA) and washed; twice in 25% (v/v) TCA, once in a solution of acetone containing HCl (200:1) and once in acetone. This pellet was solubilized in PP2A assay buffer and used at a concentration of 0.3 μM. Following different incubation times with PP2A-B55α at 30 °C (2, 5, 10 or 20 min), release of inorganic ³²P-phosphate was measured through

extraction of a phosphate–molybdate complex and scintillation counting³⁷. Under these conditions, phosphate release was < 10% of the phosphorylated substrate and thus remained in the linear range. Phosphorylase a phosphatase assays were performed as previously described³⁸, by measuring the liberated TCA-soluble ³²P-labelled phosphate following a 10- or 20-min incubation with PP2A–B55α. Each measurement of phosphatase activity was performed in triplicate. PP2A–B55α activities from mitotic cells were normalized to PP2A–B55α activities from interphase cells.

Affinity purification of protein complexes. HeLa cell pools expressing LAP-tagged mouse PP2A subunits from bacterial artificial chromosomes (BACs) were cultured in ten 25-cm square tissue culture trays. Cells were harvested from two culture conditions: prometaphase arrest induced by incubation in 0.1 µg ml⁻¹ nocodazole for 18 h and during exponential growth, yielding cells typically > 90% in interphase. PP2A complexes were isolated from concentrated extracts of these cells using the two-step purification procedure previously described²⁷, except that okadaic acid was included in the extract buffer and all subsequent solutions to inhibit auto-dephosphorylation. Purified protein complex (20%) was analysed by SDS–PAGE and silver staining. The remaining sample was processed as previously described³⁹, then divided into two aliquots for parallel in-solution digestion by trypsin and subtilisin and analysis by liquid chromatography–mass spectrometry for protein identification and phosphorylation site mapping.

Trypsin digestion of SDS–PAGE gel slices. Selected silver-stained protein bands were excised from an SDS–PAGE gel, cut into smaller pieces and washed by incubating in a shaking incubator once with 200 µl of 50 mM triethyl ammonium bicarbonate (TEAB), then once with 100 µl acetonitrile (ACN) plus 100 µl of 50 mM TEAB. Each wash step was performed in a shaking incubator at room temperature. This two-step wash procedure was repeated, and then excess liquid removed. To shrink the gel pieces, 100 µl of ACN was added.

Proteins were reduced by incubating the gel pieces in 100 µl of 1 mg ml⁻¹ DTT in 50 mM TEAB at 57 °C for 30 min, and removing the excess liquid. Proteins were alkylated by incubating the gel pieces with 100 µl of 5 mg ml⁻¹ iodoacetamide in 50 mM TEAB at room temperature, in the dark, for 35 min. Gel pieces were subjected to the two-step wash and shrinking procedures, as previously described, and were then centrifuged in a vacuum concentrator (SpeedVac, Thermo Scientific) until dry (5–7 min).

Trypsin Gold (Promega) was first dissolved to a concentration of 100 ng µl⁻¹ in 50 mM acetic acid, then diluted in 50 mM TEAB to a concentration of 12 ng µl⁻¹. Gel pieces were incubated with 20 µl trypsin–TEAB solution at 4 °C for 5 min. Excess liquid was removed, and 20 µl of 50 mM TEAB was added, followed by incubation at 37 °C overnight. After centrifugation, the supernatant was transferred into a fresh tube and stored at 5 °C. Formic acid (20 µl of a 5% (v/v) solution) was added to the gel pieces, followed by sonication for 10 min in a cooled ultrasonic waterbath. The sample was spun and the supernatant transferred to the tube. This formic acid/sonication step was repeated once, and the supernatant pooled with the first, generating a sample of volume 60 µl, ready for analysis by mass spectrometry.

Nano-liquid chromatography–mass spectrometry. The nano-HPLC (high-performance liquid chromatography) system used in all experiments was an UltiMate 3000 Dual Gradient HPLC system (Dionex), equipped with a nanospray source (Proxeon), coupled to an LTQ FT mass spectrometer (Thermo Fisher Scientific) in the first analysis and coupled to an LTQ Velos Orbitrap mass spectrometer (Thermo Fisher Scientific) in the second analysis. The LTQ FT was operated in data-dependent mode using a full scan in the ICR (ion cyclotron resonance) cell followed by tandem mass spectrometry scans of the five most abundant ions in the linear ion trap. Tandem mass spectrometry spectra were acquired in the multistage activation mode, where subsequent activation was performed on fragment ions resulting from the neutral loss of -98, -49 or -32.6 m/z. Precursor ions selected for fragmentation were put on a dynamic exclusion list for 180 s and monoisotopic precursor selection was enabled. Phosphorylated peptides identified by database search and validated by manual inspection were put onto an inclusion list and replicate analyses were carried out on an LTQ Velos Orbitrap mass spectrometer.

Analysis of mass spectrometry data. For peptide identification, all tandem mass spectrometry spectra were analysed using Mascot 2.2.0 (Matrix Science) against a customized protein sequence database comprising the complete human sequences from Swiss-Prot, TrEMBL, PIR, GenBank, EMBL, DDBJ, RefSeq and Celera (hKBMS), plus the Swiss-Prot database entries corresponding to the mouse ‘bait’ proteins. The following search parameters were used: carbamidomethylation on cysteine was set as a fixed modification, and oxidation on methionine, and phosphorylation on serine, threonine and tyrosine were set as variable modifications. Monoisotopic masses were analysed using an unrestricted range of protein masses for tryptic peptides. The peptide mass tolerance was set to ± 5 p.p.m. and the fragment mass tolerance to ± 0.5. The maximal number of missed cleavages was set to two. Each tandem mass spectrometry spectrum corresponding to a predicted phosphorylated peptide was validated by visual inspection. A label-free quantification approach was used to determine abundance change from interphase to mitosis of the different peptides by peak area integration. For peak area quantification, we extracted the ion chromatograms of the peptides with a mass tolerance of 3 p.p.m. using the Qual Browser application from the Xcalibur software package. The mass traces of peak area integration for the phosphorylated peptides shown in Fig. 5f were extracted from the base peak chromatogram with ± 3 p.p.m. mass tolerance, manually reviewed and are shown in Supplementary Information, Fig. S8.

35. Schmitz, M. H. & Gerlich, D. W. Automated live microscopy to study mitotic gene function in fluorescent reporter cell lines. *Methods Mol. Biol.* **545**, 113–134 (2009).
36. Amniai, L. *et al.* Alzheimer disease specific phosphoepitopes of Tau interfere with assembly of tubulin but not binding to microtubules. *FASEB J.* **23**, 1146–1152 (2009).
37. Shacter-Noiman, E. & Chock, P. B. Properties of a $M_r = 38,000$ phosphoprotein phosphatase. Modulation by divalent cations, ATP, and fluoride. *J. Biol. Chem.* **258**, 4214–4219 (1983).
38. Waelkens, E., Goris, J. & Merlevede, W. Purification and properties of polycation-stimulated phosphorylase phosphatases from rabbit skeletal muscle. *J. Biol. Chem.* **262**, 1049–1059 (1987).
39. Gregan, J. *et al.* Tandem affinity purification of functional TAP-tagged proteins from human cells. *Nat. Protoc.* **2**, 1145–1151 (2007).

DOI: 10.1038/ncb2092




Figure S1 Validation of automated image analysis. **(a)** Histograms of mitotic exit timing based on IBB-import after anaphase onset ($t = 0$) of the same dataset analysed manually (left, white bars), or automatically (right, black bars). **(b)** Automated annotation is highly reproducibly between movies (three independent movies shown).

SUPPLEMENTARY INFORMATION




Figure S2 Validation of RNAi efficiency. **(a-c)** Mitotic exit timing measured as in Figure 1, for six different siRNAs targeting CA ($n \geq 382$ for each siRNA condition; mean \pm s.d.) **(a)**, R1A ($n \geq 175$ for each siRNA condition) **(b)**, or B55 α ($n \geq 108$ for each siRNA condition) **(c)**. **(d-f)** Quantification of mRNA knockdown 40 h post transfection by real-time PCR for the same siRNAs as in **(a-c)**, targeting CA **(d)**, R1A **(e)**, or B55 α **(f)**, normalized against GAPDH ($n = 3$ for each condition; mean \pm s.d.). See Supplementary Information, Table 2 for

siRNA sequences. **(g)** Protein depletion levels of CA, R1A, and B55 α , detected by Western blotting in cells depleted for the indicated siRNAs 60 h post-transfection. Note that depletion of CA or R1A co-depletes other subunits of the PP2A-B55 α complex, consistent with previous reports^{39, 40}. **(h)** Quantification of Importin $\beta 1$ mRNA knockdown 48 h post transfection. **(i)** Importin $\beta 1$ protein levels, detected by Western blotting 64 h after siRNA transfection. **(j)** Quantification of B55 δ mRNA knockdown 48 h post transfection.




Figure S3 Phenotypes of B55 α single depletions. **(a)** Nuclear reassembly timing in a B55 α -depleted cell, see also Supplementary Information, Movie S11. **(b)** Golgi reassembly timing in a B55 α -depleted cell, see also

Supplementary Information, Movie S12. **(c-e)** Cumulative histograms of postmitotic Golgi clustering **(c)**, chromosome decondensation **(d)**, and spindle disassembly **(e)** relative to anaphase onset (0 min). Scale bars: 10 μ m.

SUPPLEMENTARY INFORMATION




Figure S4 Effect of PP2A-B55 α -depletion on cell cycle progression. (a) Cell cycle staging by DNA replication factor pattern of EGFP-PCNA. (b, c,

d) Cumulative histograms of G1-phase (b), S-phase (c), and G2-phase (d) duration. Scale bars: 10 μ m.




Figure S5 B55 α functions downstream of Cdk1-cyclin B inactivation.
(a) Movie of a cell transfected with non-silencing control siRNA, following the protocol indicated in Figure 4a. Arrowhead indicates onset of nuclear import of IBB-EGFP. **(b)** Time-lapse images of a cell transfected with siRNA targeting B55 α , see also Supplementary Information, Movie S13. **(c, d)** Cumulative histograms of nuclear envelope assembly

and Golgi clustering **(d)** timing based on the data shown in **(a-b, and data not shown)**. **(e)** Chemical induction of mitotic exit in presence of proteasome inhibitor in nocodazole arrested mitotic cells results in rapid dephosphorylation of Cdk substrates (siControl, lanes 1-7). Cells depleted for B55 α show delayed dephosphorylation (siB55 α , lanes 8-14). Scale bars: 10 μ m.

SUPPLEMENTARY INFORMATION




Figure S6 Expression levels and localization of PP2A-B55 α . **(a)** PP2A-B55 α subunits are expressed at constant levels during the cell cycle. Whole cell lysates were probed by Western Blotting using the antibodies against CA, R1A, and B55 α . Left lane: 17 h nocodazole arrested cells (noc), right lane:

unsynchronized interphase cells (log). Note that CA migrates as a doublet band (see also Supplementary Information, Figure S2g). **(b)** Localization of B55 α . Confocal live images of cells expressing EGFP-mouse-B55 α from endogenous promotor (see Fig. 2b). Scale bar: 10 μ m.




Figure S7 Early mitotic progression in Importin $\beta 1$ -depleted cells. Timing from prometaphase until anaphase was measured for the same cells shown in Fig. 5e.

SUPPLEMENTARY INFORMATION




Figure S8 Quantification of phosphorylation levels by extracted ion chromatograms. Extracted ion chromatograms (XICs) of phosphopeptides identified (hash indicates the phosphorylated amino acid), and their unmodified counterparts, from purified PP2A complexes. Peak-area values for the phosphopeptides were used for quantification of the mitotic increase in phosphorylation abundance, whereas those of the unmodified peptides were used for normalization, as described in the legend for Fig. 5f. The panels show: 1. XIC featuring the phosphorylated

peptide identified from the PP2A complex purified from interphase (log) cells. 2. XIC featuring the same phosphorylated peptide identified from the mitotic (noc) cell state. 3. XIC featuring the unmodified counterpart peptide from interphase. 4. XIC featuring the unmodified counterpart peptide from the mitotic (noc) cell state. **(a)** Quantitation of S554 phosphorylation on R1A. **(b)** S8 phosphorylation on R1A. **(c)** T304 phosphorylation on CA. **(d)** S212 phosphorylation on CA. **(e)** S167 phosphorylation on B55 α .




Figure S9 Full scans of blots. **(a)** Full scan for B55 α and Actin immunoblot of Figure 2b. **(b)** Full scan for phospho(Ser)Cdk substrates (upper) and Cyclin B1, Nucleolin, and Actin (lower) immunoblot of Figure 4f. **(c)** Full scan for Importin β 1 and R1A IP-blot (left) and Importin β 1 Input-blot (right) of Figure 5d. **(d)** Full scan for CA (upper left), R1A and B55 α (lower left), and loading control blots (right panels) of Figure S2g. **(e)** Full scan

for Importin β 1 and Actin immunoblot of Figure S2i. **(f)** Full scan for phospho(Ser)Cdk substrates (upper) and Cyclin B1, and Nucleolin (lower) immunoblot of Figure S5e. **(g)** Full scan for CA, R1A, and B55 α (right) and Actin (left) immunoblot of Figure S6a. (Sliced bands are indicated with arrows). **(h)** Relevance of B55 α -S167 phosphorylation for PP2A complex assembly. Independent replica of the experiment shown in Fig. 5g.

SUPPLEMENTARY INFORMATION

Supplementary Movie Legends

Movie S1 Monoclonal fluorescent HeLa cell line expressing chromatin marker H2B-mCherry and the nuclear import substrate IBB-EGFP. The movie shows 13% of the total image size and represent a typical overnight screening movie. Time-lapse covers a period of ~21 hours.

Movie S2 H2B-mCherry / IBB-EGFP reporter cell that has been automatically detected, tracked, and segmented over time. Movie shows original images (left); mitotic stage classification with color label as in Fig. 1c (middle), and regions of IBB measurements (right). Time-lapse covers a period of 216 minutes.

Movie S3 H2B-mCherry / IBB-EGFP cell treated with siControl. This movie shows mitotic progression and nuclear envelope reassembly in a control cell. Time-lapse covers a period of 192 minutes.

Movie S4 H2B-mCherry / IBB-EGFP cell treated with siPP2A-B55 α . This movie shows mitotic progression and delayed nuclear envelope reassembly in a cell depleted for PP2A-B55 α . Time-lapse covers a period of 192 minutes.

Movie S5 H2B-mCherry / GaIT-EGFP cell treated with siControl. This movie shows mitotic progression and Golgi reassembly in a control cell. Time-lapse covers a period of 132 minutes.

Movie S6 H2B-mCherry / GaIT-EGFP cell treated with siPP2A-B55 α . This movie shows mitotic progression and delayed Golgi reassembly in a cell depleted for PP2A-B55 α . Time-lapse covers a period of 161 minutes.

Movie S7 H2B-mCherry / mEGFP- α -tubulin cell treated with siControl. This movie shows mitotic progression and mitotic spindle dynamics in a control cell. Time-lapse covers a period of 108 minutes.

Movie S8 H2B-mCherry / mEGFP- α -tubulin cell treated with siPP2A-B55 α . This movie shows mitotic progression and delayed mitotic spindle disassembly in a cell depleted for PP2A-B55 α . Time-lapse covers a period of 108 minutes.

Movie S9 H2B-mCherry / IBB-EGFP cell treated with siControl. This movie shows forced mitotic exit in presence of MG132 by addition of the Cdk inhibitor flavopiridol in a control cell. Time-lapse covers a period of 47 minutes.

Movie S10 H2B-mCherry / IBB-EGFP cell treated with siPP2A-B55 α . This movie shows delayed mitotic exit in presence of MG132 by addition of the Cdk inhibitor flavopiridol in a cell depleted for PP2A-B55 α . Time-lapse covers a period of 47 minutes.

Supplementary Information Table 1. Library of siRNA oligos

genid	symbol	Qiagen product name	ernaAccessions	Qiagen product id	description	target	antisense	ensembl	ensembl
523CP1	Hs_ACP1_5	NM_004300 NM_007099 NM_177564	S026565164		acid phosphatase 1, soluble	CCTCATGTCGACATCTGTATA	UAUCAAGUUGUCACAUUUAU	CAUAGUUCGACACUUGUAU	
524CP1	Hs_ACP1_6	NM_004300 NM_007099 NM_177564	S027770855		acid phosphatase 1, soluble	ATGATGGAAACCAACTGTGAA	UCUCAAGUUGUCACAUUUAU	GGAUAGAACAUUACAUUUAU	
525CP1	Hs_ACP1_7	NM_00104049 NM_004300 NM_007099	S03068772		acid phosphatase 1, soluble	CGAAGGGCTTGTGACCCGATA	UACUCAAGUUGUCACAUUUAU	GGAUAGAACAUUACAUUUAU	
526CP2	Hs_ACP2_5	NM_001610	S026568628		acid phosphatase 2, lysosomal	CTGGATTGTCATACAGTTGTA	UACUCAAGUUGUCACAUUUAU	GGAUAGAACAUUACAUUUAU	
53ACP2	Hs_ACP2_6	NM_001610	S026568635		acid phosphatase 2, lysosomal	CAGCCTTGAGCTTCGGAAA	UUUCCGGAGACAGUUCGGCA	GCGCUAGAGUUCUGCGAAA	
54ACP2	Hs_ACP2_7	NM_001610	S030683319		acid phosphatase 2, lysosomal	CAAGAATGGAGTTCTGGGAAT	AUUCGGAGACAGUUCAUUUAU	GAUAGAACAUUACAUUUAU	
549CP2	Hs_ACP5_1	NM_001611	S026568642		acid phosphatase 5, tartrate resistant	GGGGCGAGAGTCGAGGAA	UACUCAAGUUGUCACAUUUAU	GGAUAGAACAUUACAUUUAU	
549CP3	Hs_ACP5_3	NM_001611	S026568649		acid phosphatase 5, tartrate resistant	AGCGGCTTGTGACATCTGAA	UAUCAAGUUGUCACAUUUAU	GGAUAGAACAUUACAUUUAU	
549CP4	Hs_ACP5_4	NM_001611	S026568656		acid phosphatase 5, tartrate resistant	CACTGTCGACAGCAGCTCAA	UACUCAAGUUGUCACAUUUAU	GGAUAGAACAUUACAUUUAU	
549CP5	Hs_ACP5_1	NM_001099	S020021882		acid phosphatase, prostate	CTCTATTACATTATGGATAA	UACUCAAGUUGUCACAUUUAU	GGAUAGAACAUUACAUUUAU	
549CP7	Hs_ACPP_2	NM_001099	S00021889		acid phosphatase, prostate	ACAGATGGCCCTAGATGTTA	UACUCAAGUUGUCACAUUUAU	GGAUAGAACAUUACAUUUAU	
549CP8	Hs_ACPP_3	NM_001099	S00021896		acid phosphatase, prostate	CCGGACTTGTAGTAGCTAT	UACUCAAGUUGUCACAUUUAU	GGAUAGAACAUUACAUUUAU	
248ALPI	Hs_ALPI_5	NM_001631	S026565579		alkaline phosphatase, intestinal	CGAGCTTCACTCTGGCGAA	UUUCCGGAGACAGUUCGGCA	GCGCUAGAGUUCUGCGAAA	
248ALPI	Hs_ALPI_6	NM_001631	S03083157		alkaline phosphatase, intestinal	CGCTTGGACCTTACCTCTCA	UAGAGAUGUAGGAGUUCGGCA	GUUUGACCACUACUCUUAU	
248ALPI	Hs_ALPI_7	NM_001631	S02002770		alkaline phosphatase, intestinal	UAGAGAUGUAGGAGUUCGGCA	GUUUGACCACUACUCUUAU		
248ALPI	Hs_ALPI_8	NM_001631	S02002770		alkaline phosphatase, intestinal	CGCTTGGACCTTACCTCTCA	UAGAGAUGUAGGAGUUCGGCA	GUUUGACCACUACUCUUAU	
248ALPI	Hs_ALPI_9	NM_001631	S02002770		alkaline phosphatase, intestinal	UAGAGAUGUAGGAGUUCGGCA	GUUUGACCACUACUCUUAU		
248ALPI	Hs_ALPI_10	NM_0020478	S026568600		alkaline phosphatase, liver/bone/kidney	CGCTTGGACCTTACCTCTCA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
248ALPI	Hs_ALPI_6	NM_000478	S03054907		alkaline phosphatase, liver/bone/kidney	CGAGATGGCCACATCTGTTA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
248ALPI	Hs_ALPI_3	NM_000478	S000102853		alkaline phosphatase, liver/bone/kidney	CAACATGATTCTCACCTCT	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
251ALPP2	Hs_ALPP2_5	NM_031313	S027598414		alkaline phosphatase, placental-like 2	CGAGCGCTTCCTAGAGGAA	UUUCCGGAGACAGUUCGGCG	GCGCUAGAGUUCUGCGAAA	
251ALPP2	Hs_ALPP2_1	NM_031313	S029476763		alkaline phosphatase, placental-like 2	TGGGGCTGAGGATAGGAGCTCA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
251ALPP2	Hs_ALPP2_2	NM_031313	S029476763		alkaline phosphatase, placental-like 2	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA		
251ALPP2	Hs_ALPP2_3	NM_031313	S029476763		alkaline phosphatase, placental-like 2	TGGGGCTGAGGATAGGAGCTCA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
251ALPP2	Hs_ALPP2_4	NM_031313	S029476763		alkaline phosphatase, placental-like 2	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA		
993CDC5B	Hs_CDC5B_5	NM_001789 NM_201567	S022225454		cell division cycle 25 homolog A (S. pombe)	CTGCGCATATGCCGACATCA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
993CDC5B	Hs_CDC5B_6	NM_001789 NM_201567	S026568642		cell division cycle 25 homolog A (S. pombe)	CTGCGCATATGCCGACATCA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
993CDC5B	Hs_CDC5B_4	NM_001789 NM_201567	S026568642		cell division cycle 25 homolog A (S. pombe)	CTGCGCATATGCCGACATCA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
994CDC5B	Hs_CDC5B_10	NM_004358 NM_021872 NM_021873 NM_021873 NM_021873	S026569272		cell division cycle 25 homolog B (S. pombe)	CCAGCAGTGTGTCAGTGTAGTA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
994CDC5B	Hs_CDC5B_11	NM_004358 NM_021872 NM_021873 NM_021873 NM_021873	S026569272		cell division cycle 25 homolog B (S. pombe)	CCAGCAGTGTGTCAGTGTAGTA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
994CDC5B	Hs_CDC5B_8	NM_004358 NM_021872 NM_021873 NM_021873 NM_021873	S026569272		cell division cycle 25 homolog B (S. pombe)	CCAGCAGTGTGTCAGTGTAGTA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
995CDC5C	Hs_CDC5C_5	NM_001790 NM_022809	S026568642		cell division cycle 25 homolog C (S. pombe)	CCAGGAGCTTAAAGCTTATA	UACUCAAGUUGUCACAUUUAU	GAGGGAGCUUACAAUUAU	
995CDC5C	Hs_CDC5C_9	NM_001790 NM_022809	S026568642		cell division cycle 25 homolog C (S. pombe)	CCAGGAGCTTAAAGCTTATA	UACUCAAGUUGUCACAUUUAU	GAGGGAGCUUACAAUUAU	
995CDC5C	Hs_CDC5C_10	NM_001790 NM_022809	S026568642		cell division cycle 25 homolog C (S. pombe)	CCAGGAGCTTAAAGCTTATA	UACUCAAGUUGUCACAUUUAU	GAGGGAGCUUACAAUUAU	
1033DKN3	Hs_DKN3_3	NM_005192	S026465621		cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase)	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1033DKN3	Hs_DKN3_7	NM_005192	S026465621		cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase)	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1033DKN3	Hs_DKN3_5	NM_005192	S000755653		cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase)	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1043DUSP1	Hs_DUSP_1	NM_004417	S03074801		dual specificity phosphatase 1	TAGGCGCTGAGCTTCTGGTA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
1043DUSP1	Hs_DUSP_3	NM_004417	S030748115		dual specificity phosphatase 1	CGAACAGACGCTGGCAGCTCA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
1043DUSP1	Hs_DUSP_4	NM_004417	S030748212		dual specificity phosphatase 1	CGAACAGACGCTGGCAGCTCA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
1043DUSP1	Hs_DUSP_5	NM_004417	S030748212		dual specificity phosphatase 1	CGAACAGACGCTGGCAGCTCA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
1044DUSP2	Hs_DUSP_2	NM_004418	S026465648		dual specificity phosphatase 2	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1044DUSP2	Hs_DUSP_22	NM_004418	S026465648		dual specificity phosphatase 2	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1045DUSP3	Hs_DUSP_3	NM_004490	S026659603		dual specificity phosphatase 3 (vacuina virus phosphatase Vht-related)	CCGGCTTACTTACAGAGT	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
1045DUSP3	Hs_DUSP_6	NM_004490	S026659603		dual specificity phosphatase 3 (vacuina virus phosphatase Vht-related)	CCGGCTTACTTACAGAGT	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
1045DUSP3	Hs_DUSP_1	NM_004490	S000561612		dual specificity phosphatase 3 (vacuina virus phosphatase Vht-related)	CCGGCTTACTTACAGAGT	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
1046DUSP4	Hs_DUSP_4	NM_004490	S026659603		dual specificity phosphatase 4	TAGGTTAGTATGATGATGAA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
1046DUSP4	Hs_DUSP_3	NM_004490	S026659603		dual specificity phosphatase 4	TAGGTTAGTATGATGATGAA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
1046DUSP4	Hs_DUSP_5	NM_004490	S026659603		dual specificity phosphatase 4	TAGGTTAGTATGATGATGAA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
1047DUSP5	Hs_DUSP_6	NM_004491	S026465648		dual specificity phosphatase 5	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1047DUSP5	Hs_DUSP_8	NM_004491	S026465648		dual specificity phosphatase 5	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1047DUSP5	Hs_DUSP_10	NM_004491	S026465648		dual specificity phosphatase 5	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1048DUSP5	Hs_DUSP_6	NM_004491	S026465648		dual specificity phosphatase 5	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1048DUSP5	Hs_DUSP_8	NM_004491	S026465648		dual specificity phosphatase 5	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1048DUSP5	Hs_DUSP_10	NM_004491	S026465648		dual specificity phosphatase 5	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1049DUSP7	Hs_DUSP_7	NM_001947	S026465648		dual specificity phosphatase 7	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1049DUSP7	Hs_DUSP_9	NM_001947	S026465648		dual specificity phosphatase 7	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1049DUSP7	Hs_DUSP_11	NM_001947	S026465648		dual specificity phosphatase 7	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1049DUSP7	Hs_DUSP_12	NM_001947	S026465648		dual specificity phosphatase 7	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1049DUSP7	Hs_DUSP_13	NM_001947	S026465648		dual specificity phosphatase 7	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1049DUSP7	Hs_DUSP_14	NM_001947	S026465648		dual specificity phosphatase 7	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1049DUSP7	Hs_DUSP_15	NM_001947	S026465648		dual specificity phosphatase 7	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1049DUSP7	Hs_DUSP_16	NM_001947	S026465648		dual specificity phosphatase 7	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1049DUSP7	Hs_DUSP_17	NM_001947	S026465648		dual specificity phosphatase 7	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1049DUSP7	Hs_DUSP_18	NM_001947	S026465648		dual specificity phosphatase 7	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1049DUSP7	Hs_DUSP_19	NM_001947	S026465648		dual specificity phosphatase 7	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
1049DUSP7	Hs_DUSP_20	NM_001947	S026465648		dual specificity phosphatase 7	UACUCAAGUUGUCACAUUUAU	TGCGGCAAAATAGTGCACACA	GCGCUAGAGUUCUGCGAAA	
2203FBP1	Hs_FBP1_5	NM_000507	S026564648		fructose-1,6-bisphosphatase 1	TTCTTCTGAGCTGAGGAA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
2203FBP1	Hs_FBP1_6	NM_000507	S026564648		fructose-1,6-bisphosphatase 1	TTCTTCTGAGCTGAGGAA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
2203FBP1	Hs_FBP1_7	NM_000507	S026564648		fructose-1,6-bisphosphatase 1	TTCTTCTGAGCTGAGGAA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
2203FBP1	Hs_FBP1_8	NM_000507	S026564648		fructose-1,6-bisphosphatase 1	TTCTTCTGAGCTGAGGAA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
2203FBP1	Hs_FBP1_9	NM_000507	S026564648		fructose-1,6-bisphosphatase 1	TTCTTCTGAGCTGAGGAA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
2203FBP1	Hs_FBP1_10	NM_000507	S026564648		fructose-1,6-bisphosphatase 1	TTCTTCTGAGCTGAGGAA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
2203FBP1	Hs_FBP1_11	NM_000507	S026564648		fructose-1,6-bisphosphatase 1	TTCTTCTGAGCTGAGGAA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
2203FBP1	Hs_FBP1_12	NM_000507	S026564648		fructose-1,6-bisphosphatase 1	TTCTTCTGAGCTGAGGAA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
2203FBP1	Hs_FBP1_13	NM_000507	S026564648		fructose-1,6-bisphosphatase 1	TTCTTCTGAGCTGAGGAA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
2203FBP1	Hs_FBP1_14	NM_000507	S026564648		fructose-1,6-bisphosphatase 1	TTCTTCTGAGCTGAGGAA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
2203FBP1	Hs_FBP1_15	NM_000507	S026564648		fructose-1,6-bisphosphatase 1	TTCTTCTGAGCTGAGGAA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
2203FBP1	Hs_FBP1_16	NM_000507	S026564648		fructose-1,6-bisphosphatase 1	TTCTTCTGAGCTGAGGAA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
2203FBP1	Hs_FBP1_17	NM_000507	S026564648		fructose-1,6-bisphosphatase 1	TTCTTCTGAGCTGAGGAA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
2203FBP1	Hs_FBP1_18	NM_000507	S026564648		fructose-1,6-bisphosphatase 1	TTCTTCTGAGCTGAGGAA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
2203FBP1	Hs_FBP1_19	NM_000507	S026564648		fructose-1,6-bisphosphatase 1	TTCTTCTGAGCTGAGGAA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
2203FBP1	Hs_FBP1_20	NM_000507	S026564648		fructose-1,6-bisphosphatase 1	TTCTTCTGAGCTGAGGAA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
2203FBP1	Hs_FBP1_21	NM_000507	S026564648		fructose-1,6-bisphosphatase 1	TTCTTCTGAGCTGAGGAA	UACUCAAGUUGUCACAUUUAU	GCGCUAGAGUUCUGCGAAA	
2203FBP1	Hs_FBP1_22	NM_000507							

54704	PPM2C	Hs	PPM2C_5	NM_018444	SI02759372	protein phosphatase 2C, magnesium-dependent, catalytic subunit	ATCGTACCTTCATTATAGTAA	UUACUAAAUAAGAACUACGat	CGUACUUCUAAUUAAGUAUAA
54705	PPM2C	Hs	PPM2C_4	NM_018444	SI02759373	protein phosphatase 2C, magnesium-dependent, regulatory subunit	GGAAAGGAGGAGGAGGAGGAG	GGAAAGGAGGAGGAGGAGGAG	GGAAAGGAGGAGGAGGAGGAG
54778	PPPIB12C	Hs	PPPIB12C_5	NM_017967	SI02776962	protein phosphatase, 1, regulatory (inhibitor) subunit 12C	CACAGGGACCTTCGAGAACCAA	UUCGUUGAGGAGGAGGAGGAG	CGGAGGGAGGAGGAGGAGGAG
54778	PPPIB12C	Hs	PPPIB12C_6	NM_017967	SI0303750	protein phosphatase, 1, regulatory (inhibitor) subunit 12C	ACCGACGGAGGAGTACCCAGA	UUCGUUGAGGAGGAGGAGGAG	CGGAGGGAGGAGGAGGAGGAG
54778	PPPIB12C	Hs	PPPIB12C_7	NM_017967	SI03087698	protein phosphatase, 1, regulatory (inhibitor) subunit 12C	CAGGGAGCTTTAGGACCGCTGA	UACAGGGAGGAGGAGGAGGAG	GAGGGAGGAGGAGGAGGAG
54866	PPPIB14D	Hs	PPPIB14D_1	NM_017726	SI03011943	protein phosphatase, 1, regulatory (inhibitor) subunit 14D	CCGCGCTGACAGTGAGGTGAA	UACAGGGAGGAGGAGGAGGAG	CGGCGCTGACAGTGAGGTGAA
54866	PPPIB14D	Hs	PPPIB14D_2	NM_017726	SI030119441	protein phosphatase, 1, regulatory (inhibitor) subunit 14D	CAGGGAGCTCTCCAGAGGATCA	UUCGUUGAGGAGGAGGAG	GAGGGAGGAGGAGGAGGAG
54866	PPPIB14D	Hs	PPPIB14D_5	NM_017726	SI03045546	protein phosphatase, 1, regulatory (inhibitor) subunit 14D	AGGGAGCATTTGCTACAGTCA	UAGAGGAGGAGGAGGAGGAG	AGGGAGCATTTGCTACAGTCA
54893	DUSP23	Hs	DUSP23	NM_017923	SI02974895	dual specificity phosphatase 23	CGATTCATCCAGGAGGAGAA	UUACGUUCUAAUUAAGAACG	GGGUACUCCAGGAGGAGAA
54893	DUSP23	Hs	DUSP23	NM_017923	SI03027590	dual specificity phosphatase 23	GGGGGGGGGGGGGGGGGGGG	GGGGGGGGGGGGGGGGGGGG	GGGGGGGGGGGGGGGGGGGG
54906	PPDR	Hs	PPDR_5	NM_017990	XM_001134215	pyruvate dehydrogenase phosphatase regulatory subunit	ATCTCTATCTCCGTGATA	UUACUAAAAGGGAGUAGGAG	CUCUCAUUCUCCUCAUUAU
55066	PPDR	Hs	PPDR_6	NM_017990	XM_001134215	pyruvate dehydrogenase phosphatase regulatory subunit	CAAGGGGTGTCACCTTGTGATA	UUACUAAAAGGGAGUAGGAG	AAGGGUGUGACUCCGGUCAU
55066	PPDR	Hs	PPDR_7	NM_017990	SI03068546	pyruvate dehydrogenase phosphatase regulatory subunit	CAGCATGACAGCACGACTAAC	UUUCGUAGGUGUCCAUACG	CGAUCAGCACGACUCAAA
55183	RIF1	Hs	RIF1_1	NM_018151	SI07052227	RAF1 interacting factor homolog (yeast)	CTCATGAGAAATTCTTAA	UUACUAAAUAAGGAAUACG	CGAUCAUUUAAGGAAUACG
55183	RIF1	Hs	RIF1_2	NM_018151	SI07052234	RAF1 interacting factor homolog (yeast)	AGGAAGGATCTGATGAGTAA	UUACUAAAUAAGGAAUACG	GGAAAGCAGGAGUAGGAAU
55183	RIF1	Hs	RIF1_3	NM_018151	SI07052234	RAF1 interacting factor homolog (yeast)	UUACUAAAUAAGGAAUACG	GGAAAGCAGGAGUAGGAAU	GGAAAGCAGGAGUAGGAAU
55201	SAP33	Hs	C10orf23	NM_018312	SI0317331	SAPS domain family, member 3	CGACGAGCATCTTGTGTTTA	UUACUAAAUAAGGAAUACG	GGAAAGCAGGAGUAGGAAU
55201	SAP33	Hs	C10orf23	NM_018312	SI0317331	SAPS domain family, member 3	AGAAAGAAGATGCTGACCTAA	UUACUAAAUAAGGAAUACG	GGAAAGCAGGAGUAGGAAU
55370	PPPR4L	Hs	PPPR4L_1	NM_018498	NR_003505	protein phosphatase 4, regulatory subunit 1-like	CGGCAGCTTGACATAGATGAA	UUACUAAAUAAGGAAUACG	GGACGUUCUAGGACUAAU
55370	PPPR4L	Hs	PPPR4L_2	NM_018498	SI03091156	protein phosphatase 4, regulatory subunit 1-like	AGGCAGCATTTATGAAACCAA	UUACUAAAUAAGGAAUACG	GGACGUUCUAGGACUAAU
55370	PPPR4L	Hs	PPPR4L_3	NM_018498	SI03091159	protein phosphatase 4, regulatory subunit 1-like	GGAGATTAACAGGATTCATTA	UUACUAAAUAAGGAAUACG	GGACGUUCUAGGACUAAU
55607	PPTR5A	Hs	PPTR5A_2	NM_017550	XM_374833	protein phosphatase, 1, regulatory (inhibitor) subunit 8A	GGAGGGATTTATTTCTGAA	UUACUAAAUAAGGAAUACG	GGACGUUCUAGGACUAAU
55607	PPTR5A	Hs	PPTR5A_3	NM_017550	XM_374833	protein phosphatase, 1, regulatory (inhibitor) subunit 8A	GGGGGGGGGGGGGGGGGGGG	GGGGGGGGGGGGGGGGGGGG	GGGGGGGGGGGGGGGGGGGG
55607	PPTR5A	Hs	PPTR5A_6	NM_017550	XM_374833	protein phosphatase, 1, regulatory (inhibitor) subunit 8A	CGGGGGGGGGGGGGGGGGGG	GGGGGGGGGGGGGGGGGGGG	GGGGGGGGGGGGGGGGGGGG
55613	MTMR8	Hs	MTMR8_3	NM_017677	SI02859223	myotubularin related protein 8	CGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55613	MTMR8	Hs	MTMR8_6	NM_017677	SI02859230	myotubularin related protein 8	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55613	MTMR8	Hs	MTMR8_8	NM_017677	SI02859230	myotubularin related protein 8	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_1	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_2	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_3	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_4	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_5	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_6	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_7	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_8	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_9	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_10	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_11	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_12	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_13	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_14	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_15	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_16	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_17	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_18	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_19	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_20	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_21	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_22	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_23	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_24	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_25	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_26	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_27	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_28	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_29	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_30	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_31	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_32	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_33	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_34	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_35	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_36	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_37	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_38	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_39	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_40	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_41	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_42	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_43	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_44	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_45	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_46	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_47	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_48	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_49	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_50	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_51	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_52	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_53	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_54	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_55	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAGCTTCGAGGATCTA
55625	YLP1M	Hs	YLP1M_56	NM_018589	XM_085151	YLP1M containing 1	GGGGGGAGCTTCGAGGATCTA	UUACUAAAUAAGGAAUACG	GGGGGGAG

170954	KIAA1949	Hs	KIAA1949_4	NM_133471 XM_929887 XM_934035 XM_S002824423	KIAA1949	TCCGGTCAGGCCGAGAGAAA	UUUUCUCUGGCCUCAACGgg	CGUUCGAGCCGAGAGAAAH	
201562	PTPLB	Hs	PTPLB_5	NM_198402	protein tyrosine phosphatase-like (proline instead of catalytic arginine), member b	CAAGGGCTACGGGGTCATCTTA	UAGAUUACCUUACACGGGgg	CGGGGACCUUGUGCAUCUAA	
201562	PTPLB	Hs	PTPLB_4	NM_198402	protein tyrosine phosphatase-like (proline instead of catalytic arginine), member b	GGGGGGGGGGGGGGGGGGGGGG	UUCGGGGGGGGGGGGGGGGGGGG	GGGGGGGGGGGGGGGGGGGGGG	
201562	PTPLB	Hs	PTPLB_3	NM_198402	protein tyrosine phosphatase-like (proline instead of catalytic arginine), member b	TACGCTTAACTCTCTATGGAT	AUCGUACUAGAAAGUAGGGgg	CGGUUAACUUCUUCUGCAU	
286262	Clnorf75	Hs	Clnorf75_1	NM_173691	S003339655	chromosome 9 open reading frame 75	CTCCTCAAAGAAAAGATGAA	UUCUACUULCUCUUCUGAGGgg	CGUCAAAAGAACAUAAAH
286262	Clnorf75	Hs	Clnorf75_2	NM_173691	S00333972	chromosome 9 open reading frame 75	CACAGCTGGTCCCCAAAGGGAA	UUCUCLCUCUUGGCCACCUUgg	CAGUGGGUGCCCAAAGGGAAH
286262	Clnorf75	Hs	Clnorf75_3	NM_173691	S00333979	chromosome 9 open reading frame 75	TGCAAATTCTTCATGGTCAT	AUGACCAUAGAAAGAAUUUCgg	GAAGAUUCUUCUCAUGUGCAUR
391025	LOC391025	Hs	LOC391025_5	NM_00131226 XM_372775	S00436859	similar to protein tyrosine phosphatase, receptor type, U isoform 2 precursor	CCCGCGAGGAAGCCGATGAGACGA	UCGUUCAUCCGGCUUCUCCgg	GCAGGAAGCCGAUAAAGAA
391025	LOC391025	Hs	LOC391025_6	NM_00131226 XM_372775	S00436866	similar to protein tyrosine phosphatase, receptor type, U isoform 2 precursor	CCCATGTAGTGAGCACATGGG	UCCAUUGUUCUCAUCUAGUgg	ACAUAGUAGGACCAUAGAA
391025	LOC391025	Hs	LOC391025_7	NM_00131226 XM_372775	S00436873	similar to protein tyrosine phosphatase, receptor type, U isoform 2 precursor	CCCTGTGCTCTATAGACGCTCA	UGAGGUUCUACAUACGAGgg	UGUCUCUUAAGACGACUAA
400927	LOC400927	Hs	LOC400927_1	NM_001034843 NR_002821 XM_378010	S00548667	TPTE and PTEN homologous inositol lipid phosphatase pseudogene	TCCTGTTCTCTCTCTCTCTCT	UUCGUUCUUCUUCUUCUUCUUC	CGAUGUUCUUCUUCUUCUUCUUC
400927	LOC400927	Hs	LOC400927_2	NM_001034843 NR_002821 XM_378010	S00548674	TPTE and PTEN homologous inositol lipid phosphatase pseudogene	ATGGATGTTCTCTCTGGAGTA	UACUCGAAAGAAACAUUCgg	CGAUGUUCUUCUUCUUCUUCUUC
400927	LOC400927	Hs	LOC400927_3	NM_001034843 NR_002821 XM_378010	S00548674	TPTE and PTEN homologous inositol lipid phosphatase pseudogene	TCCACAGACAAACGATTAA	UUAALUUCUUCUUCUUCUUCUUC	CACAGACAAACGAAUUAH

Supplementary Information Table 2. SiRNA oligos targeting PP2A-B55 α , B55 δ , and Importin β 1.

Entrez Gene ID	NCBI gene symbol	Symbol used this study	Gene Description	mRNA Accessions	siRNA Target Sequence	Qiagen Product ID	Product Name	mRNA knockdown this study
5515	PPP2CA	CA_3	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	NM_002715	ACACCTCGTGAATACAATTAA	SI00041853	Hs PPP2CA_3	81%
5515	PPP2CA	CA_5	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	NM_002715	ATGGAACITGAGATACTCTA	SI02225763	Hs PPP2CA_5	86%
5515	PPP2CA	CA_6	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	NM_002715	CAAACAACTATTGGAGCTTA	SI02225790	Hs PPP2CA_6	87%
5515	PPP2CA	CA_7	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	NM_002715	TAAGACGATGTGACTGCACAA	SI04436453	Hs PPP2CA_7	78%
5515	PPP2CA	CA_8	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	NM_002715	ATGGTGTCTCTGCCATCTA	SI04436460	Hs PPP2CA_8	74%
5515	PPP2CA	CA_9	protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	NM_002715	TACAAAGCCTCTGTCTCAA	SI04436467	Hs PPP2CA_9	80%
5518	PPP2R1A	R1A_1	protein phosphatase 2 (formerly 2A), regulatory subunit A, alpha isoform	NM_014225	TCCCCATCTGGGCAAAGACAA	SI00103733	Hs PPP2R1A_1	94%
5518	PPP2R1A	R1A_5	protein phosphatase 2 (formerly 2A), regulatory subunit A, alpha isoform	NM_014225	CTGGTGTCCGATGCCAACAA	SI02225811	Hs PPP2R1A_5	91%
5518	PPP2R1A	R1A_6	protein phosphatase 2 (formerly 2A), regulatory subunit A, alpha isoform	NM_014225	ACGGCTGAACATCATCTCTAA	SI02225818	Hs PPP2R1A_6	71%
5518	PPP2R1A	R1A_7	protein phosphatase 2 (formerly 2A), regulatory subunit A, alpha isoform	NM_014225	GACCAGGATGTGGACGTCAAA	SI04436495	Hs PPP2R1A_7	95%
5518	PPP2R1A	R1A_8	protein phosphatase 2 (formerly 2A), regulatory subunit A, alpha isoform	NM_014225	ATGCCGGTGTCTAGAGCAGAA	SI04436502	Hs PPP2R1A_8	89%
5518	PPP2R1A	R1A_9	protein phosphatase 2 (formerly 2A), regulatory subunit A, alpha isoform	NM_014225	CACCTTGACAGAGTGAAGTCAA	SI04436509	Hs PPP2R1A_9	97%
5520	PPP2R2A	R2A_1	protein phosphatase 2 (formerly 2A), regulatory subunit B, alpha isoform	NM_002717	CTCGCCGTGCTCGCACTGAA	SI00041895	Hs PPP2R2A_1	72%
5520	PPP2R2A	R2A_3	protein phosphatase 2 (formerly 2A), regulatory subunit B, alpha isoform	NM_002717	AAGCGAGACATAACCCCTAGAA	SI00041909	Hs PPP2R2A_3	76%
5520	PPP2R2A	R2A_5	protein phosphatase 2 (formerly 2A), regulatory subunit B, alpha isoform	NM_002717	CTGCAGATGATTGCCGGATTA	SI02225825	Hs PPP2R2A_5	95%
5520	PPP2R2A	R2A_6	protein phosphatase 2 (formerly 2A), regulatory subunit B, alpha isoform	NM_002717	ATGGAAGGTATAGAGATCTCA	SI02225832	Hs PPP2R2A_6	94%
5520	PPP2R2A	R2A_7	protein phosphatase 2 (formerly 2A), regulatory subunit B, alpha isoform	NM_002717	CCCGGGCTTTGTTGTTGATA	SI04436516	Hs PPP2R2A_7	77%
5520	PPP2R2A	R2A_8	protein phosphatase 2 (formerly 2A), regulatory subunit B, alpha isoform	NM_002717	CAGTCTCATAGCAGAGGGAA	SI04436523	Hs PPP2R2A_8	93%
55844	PPP2R2D	B55 δ	protein phosphatase 2, regulatory subunit B, delta isoform	NM_001003656 NM_018461	CAGAGACTACCTGTCGGTGA	SI00691523	Hs PPP2R2D_1	72%
55844	PPP2R2D	B55 δ	protein phosphatase 2, regulatory subunit B, delta isoform	NM_001003656 NM_018461	CCGCTCCATTAAAGAACAGTGA	SI00691530	Hs PPP2R2D_2	52%
55844	PPP2R2D	B55 δ	protein phosphatase 2, regulatory subunit B, delta isoform	NM_001003656 NM_018461	TTCATCCATTCGGATGTAAA	SI02759148	Hs PPP2R2D_5	82%
3837	KPNB1	Importin β 1	karyopherin (importin) beta 1	NM_002265	TCGGTTATTTGCCAAGATA	SI00035490	Hs_KPNB1_1	89%
3837	KPNB1	Importin β 1	karyopherin (importin) beta 1	NM_002265	CAAGAACTCTTGACATCTAA	SI00035497	Hs_KPNB1_2	90%
3837	KPNB1	Importin β 1	karyopherin (importin) beta 1	NM_002265	AAAGGGCGGAGATCGAAGACTA	SI00035504	Hs_KPNB1_3	89%

red = used for single or triple knockdown, this study.

Supplementary Information Table 3. Plasmids generated for this study

For efficient generation of cell lines stably expressing fluorescently tagged marker proteins, the genes were subcloned into pIRES-puro2 and pIRES-neo3 vectors (Clontech) that allow expression of resistance genes and tagged proteins from a single transcript.

Table 3. Generated plasmids

Plasmid name	Tag	Source plasmids	Vector backbone	Backbone cloning sites
pIBB-mEGFP-IRES-puro2b	mEGFP ¹	pIBB-mEGFP ²	pIRES-puro2b	EcoRI/NotI
pGalT-GFP-IRES-puro2b	GFP	pGalT-GFP (MluI blunted/EcoRI) ³	pIRES-puro2b	(NotI blunted/EcoRI)
pEGFP-PCNA-IRES-puro2b	mEGFP ¹	pNLS-EGFP-PCNA ⁴	pIRES-puro2b	(NdeI, XbaI)

mEGFP indicates monomeric EGFP.

Supplementary Information Table 4. Monoclonal fluorescent reporter cell lines

Stable cell lines were generated as described in ⁵.

Table 4. HeLa Kyoto monoclonal cell lines

Background	Cell line name	Plasmid 1	Plasmid 2
HeLa ‘Kyoto’	H2B-mCherry	pH2B-mCherry-IRES-neo3	-
HeLa ‘Kyoto’	H2B-mCherry and IBB-mEGFP	pH2B-mCherry-IRES-neo3	pIBB-mEGFP-IRES-puro2b
HeLa ‘Kyoto’	H2B-mCherry and GalT-GFP	pH2B-mCherry-IRES-neo3	pGalT-GFP-IRES-puro2b
HeLa ‘Kyoto’	H2B-mCherry and PCNA-mEGFP	pH2B-mCherry-IRES-neo3	pPCNA-mEGFP-IRES-puro2b
HeLa ‘Kyoto’	H2B-mCherry and mEGFP-α-tubulin ⁶	pH2B-mCherry-IRES-neo3	pmEGFP-α-tubulin-IRES-puro2b

Supplementary references

1. Snapp, E.L. *et al.* Formation of stacked ER cisternae by low affinity protein interactions. *J Cell Biol* **163**, 257-269 (2003).
2. Dultz, E. *et al.* Systematic kinetic analysis of mitotic dis- and reassembly of the nuclear pore in living cells. *J Cell Biol* **180**, 857-865 (2008).
3. Schaub, B.E., Berger, B., Berger, E.G. & Rohrer, J. Transition of galactosyltransferase 1 from trans-Golgi cisterna to the trans-Golgi network is signal mediated. *Mol Biol Cell* **17**, 5153-5162 (2006).
4. Leonhardt, H. *et al.* Dynamics of DNA replication factories in living cells. *J Cell Biol* **149**, 271-280. (2000).
5. Schmitz, M. & Gerlich, D. Automated live microscopy to study mitotic gene function. *Methods in Molecular Biology*, In press (2007).
6. Steigemann, P. *et al.* Aurora B-mediated abscission checkpoint protects against tetraploidization. *Cell* **136**, 473-484 (2009).